

AD _____

Award Number: DAMD17-97-1-7112

TITLE: Hereditary Breast Cancer: Mutations Within BRCA1 and
BRCA2 with Phenotypic Responses

PRINCIPAL INVESTIGATOR: Henry T. Lynch, M.D.

CONTRACTING ORGANIZATION:

Creighton University
Omaha, Nebraska 68178

REPORT DATE: July 2002

TYPE OF REPORT: Final Addendum

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030701 168

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2002	3. REPORT TYPE AND DATES COVERED Final Addendum (1 Jul 97 - 30 Jun 02)	
4. TITLE AND SUBTITLE Hereditary Breast Cancer: Mutations Within BRCA1 and BRCA2 with Phenotypic Responses			5. FUNDING NUMBERS DAMD17-97-1-7112	
6. AUTHOR(S) Henry T. Lynch, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Creighton University Omaha, Nebraska 68178 E-Mail: htlynch@creighton.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) From 85 hereditary breast cancer families, 285 invasive breast carcinomas from patients with known BRCA1/2 mutations were analyzed for histo-pathological features, c-erbB2, estrogen receptor (ER) and progesterone receptor (PR) expression. This study confirms previous data showing that BRCA1 HBC displays an aggressive biological phenotype characterized by high S-phase fraction and low estrogen and progesterone receptor expression suggesting that BRCA1 breast cancer generally will not respond well to therapy with hormone receptor modulators such as tamoxifen. C-erbB2 oncoprotein expression was low, however, which may partially explain why BRCA1 HBC tends to have a prognosis no worse than nHBC. BRCA2 cancers showed a slightly lower average S-phase fraction and higher degree of steroid hormone receptor expression than BRCA1 cancers, but also showed a level of c-erbB2 expression about 2.5 times higher than seen in sporadic breast cancer (48% of cases vs. 16-20% of cases). This suggests a somewhat more aggressive BRCA2 phenotype than previously thought and underscores the importance of c-erbB2 testing in HBC and nHBC.				
14. SUBJECT TERMS breast cancer, BRCA1, BRCA2				15. NUMBER OF PAGES 29
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	9
References.....	12
Appendices.....	20

INTRODUCTION

Even before the discovery and isolation of the major breast cancer genes *BRCA1* and *BRCA2*, there were clues that the pathology of HBC differed from that of its sporadic counterpart.¹ Earlier work showed 1) more medullary carcinoma -- a proliferative, high-grade special type with good prognosis -- in familial and HBC settings²⁻⁵; 2) a higher mitotic grade in the no special type (NST, or ductal) invasive carcinoma in HBC^{1,3}; 3) a statistically insignificant association of invasive lobular⁶⁻⁸ or tubular^{9,10} carcinomas in familial settings; and 4) conflicting positive^{11,12} and negative⁶ associations of lobular carcinoma *in situ* (LCIS) with family history. Only one of these, a positive association, was statistically significant.^{1,11}

BODY

As of the end of this study 285 cases from 85 families with a *BRCA1* or *BRCA2* mutation were identified and used for the following analysis.

The BRCA1 HBC Phenotype

At Creighton University, the authors have been investigating the clinical and pathological features of HBC with one of the largest and most longstanding pathology resources. By 1994, sufficient linkage information on *BRCA1* had become available to assign the high mitotic grade of the NST carcinomas in the cohort³ to the *BRCA1*-related HBC subset.^{1,13-16} This result has been confirmed in all subsequent studies of *BRCA1* HBCs (Table 1).¹⁷⁻²⁰ The early claim that the high mitotic grade segregates with mutations in the two terminus regions of the gene²¹ has not been confirmed by other groups,^{20,22,23} and we do not see such an effect in the Creighton data set

(J.N.M., unpublished data). In addition to mitotic grade, tubular and nuclear grades also are increased in *BRCA1* HBC (Table 1).

The excess of medullary and atypical medullary carcinomas, which had long been observed in the Creighton HBC cases,⁴ was assigned by the authors to the *BRCA1* subset shortly after the gene was isolated.^{13,15,16} This result was confirmed by the Breast Cancer Linkage Consortium¹⁷ and other groups (Table 1).^{24,25} Like HBC, medullary carcinoma is more common in early onset breast cancer,¹ but the excess of medullary and atypical medullary carcinoma in *BRCA1* HBC is independent of this age covariate.^{13,17} Compared with sporadic breast cancers¹⁵ or with *BRCA2* HBC (Table 2), *BRCA1* HBC shows significantly more of a superfamily of types which we term “medullary group” carcinomas (medullary, atypical medullary, and NST with medullary features). These have in common a heavy infiltration of lymphocytes and plasma cells in the tumor stroma. The Breast Cancer Linkage Consortium has confirmed that stromal mononuclear cell infiltration is a feature of *BRCA1* HBC.¹⁹

BRCA1 HBC shows a deficit of *in situ* carcinoma compared with non-HBC (Table 1).^{13,17} The prevalence of *BRCA1* and *BRCA2* mutations in women under age 50 is much lower for those with DCIS (13%) than invasive breast cancer (24%) ($p = 0.0007$).²⁶ We have also found a deficit in low grade special type carcinomas which we call “tubular-lobular group,” or TLG, carcinomas, comprised of lobular, tubulolobular, tubular, and invasive cribriform types (Tables 1 and 2). These special types were considered together (see Marcus et al.¹⁶ and references therein) because they share certain histological features (including the hybrid type, tubulolobular), secretory properties, epidemiological risk factors, an association with family history in earlier reports, and in the case of lobular carcinoma, a virtual lack of somatic alteration at the 17q *BRCA1* site and more microsatellite instability, in contrast to ductal carcinomas.

As further evidence for a proliferative phenotype, the authors found that a high DNA S-phase fraction originally observed in the whole HBC cohort²⁷ was confined to the *BRCA1* subset.^{1,13,15} Jóhannsson et al.²² have confirmed this observation (Table 1). The Creighton data also showed that *BRCA1* HBC is more prevalently aneuploid than non-HBC, and that the average aneuploid DNA index is less compared with non-HBC (Table 1).^{13,15,16} p53 tumor suppressor protein is more frequently increased in *BRCA1* breast cancers compared with sporadic breast cancers.^{20,28-30} This had been observed earlier in the Creighton breast-ovary HBC family cases,³¹ most of which were later identified as *BRCA1* HBC. Overexpression of p53, almost always the result of a mutation in the *TP53* gene, has been observed in general in highly proliferating breast carcinomas.³² The *TP53* mutations in *BRCA1* and *BRCA2* breast cancers are unusual in that most of them are not in usual “hotspots,” and are distributed in a region of the protein on the opposite side of its DNA-binding surface.³³

Jóhannsson et al.²² showed that *BRCA1* HBCs have decreased expression of estrogen receptor, progesterone receptor, and *c-erb-B2* (*Her2/neu*) oncoprotein (Table 1). These results have been confirmed by the Breast Cancer Linkage Consortium²⁹ and by us (N. Lehman, unpublished data).

All of the evidence thus indicates a remarkable proliferative phenotype in *BRCA1* breast cancers, and high proliferation rates are a characteristic of the ovarian carcinomas in the Creighton families with breast-ovary (and mostly *BRCA1*) HBC as well.³⁴ The distinctive pathobiology of *BRCA1* HBC can be understood in context with a model of tumor genetic evolution. In the model,^{35,36} intermediate and transformed cells suffer small losses or gains of chromosomal material while remaining near diploid in DNA content (DNA index = DI ~1). At some point the chromosome complement endoreduplicates to near-tetraploidy (DI ~2), with

continuing and more severe segmental or complete chromosomal loss, which progressively lessens the DI. In this scenario, hyperdiploid breast cancers with $1.3 \leq DI \leq 1.7$, higher S phase fractions, and p53 mutations are among the most “evolved.”³⁷⁻³⁹ The *BRCA1* phenotype – aneuploidy, lower aneuploid DI (see Table 2), high proliferation, and p53 overexpression – fits the profile of a genetically evolved tumor. In order to evolve genetically, the target cell must proliferate. In the model, the *BRCA1* mutation would put the intermediate target cell^{40,41} on a fast track of increased or unregulated proliferation, beginning near the time of menarche. At transformation, the intrinsic high proliferation rate is locked in to the tumor as a fossil phenotype of the intermediate cell.⁴² The BRCA1 protein fulfills the role required in this model. When mutated, its well-established antiproliferative function⁴³⁻⁴⁵ is lost, which may send the target cells into unregulated proliferation.

The BRCA2 HBC Phenotype

The *BRCA2* HBC phenotype is less well determined than that of *BRCA1* HBC because there are fewer cases and probably greater intrinsic heterogeneity, leading to less concordance in the literature. Most studies agree that the age of onset is significantly greater than in *BRCA1* HBC (Table 2), but still considerably less than in non-HBC. All studies agree that there is a lesser propensity for the NST (ductal) carcinomas to form tubules (Table 2), as in *BRCA1* HBC. The pathologists in the blinded Creighton studies^{13,15,16} (J.N.M. and D. L. Page) have made special efforts to not underdiagnose the tubular-lobular group (TLG) carcinomas. They find that TLG group carcinoma is a powerful discriminator between *BRCA1* and *BRCA2* HBC, scarce in the former but prevalent in the latter (Table 2). Consistent with this result, Armes et al.²⁴ also find

increased lobular carcinoma in *BRCA2* HBC, but other groups do not,^{17,46} for reasons that may relate to differing diagnostic thresholds or to intrinsic differences in the data sets.

The Breast Cancer Linkage Consortium¹⁷ claims a higher grade for *BRCA2* HBC than for the age-matched non-HBC controls, but this result is questionable. Higher nuclear, mitotic, and total grades are not seen in the large Creighton data set displayed in Table 2. The problem is that the Consortium *BRCA2* pathology data set is dominated by the Icelandic founder 999del5 mutation, which comprises nearly half (49%) of its cases. The pathology associated with this mutation, reported in a separate publication by non-Consortium pathologists,⁴⁶ is remarkable for very high grades which do not appear typical of the non-999del5 *BRCA2* cases in other data sets. Because the Consortium cases are so heavily weighted with this specific mutation, its overall results may be skewed toward higher grade. Thus, despite its large size, the Consortium data base may not be representative of *BRCA2* HBC at large. On the other hand, the fact that this argument can be made is itself evidence that *BRCA2* HBC phenotype, at least insofar as the 999del5 mutation is concerned, is heterogeneous.

In the Creighton *BRCA2* HBC data set, there is prevalent lobular neoplasia, defined as lobular carcinoma in situ or atypical lobular hyperplasia. In one *BRCA2* HBC family, 10 of 13 invasive breast carcinomas were associated with lobular neoplasia. Of interest, TLG carcinomas have a high prevalence of lobular neoplasia (see Marcus et al.¹⁶ and references therein). The DNA cytometric characteristics of *BRCA2* HBC differ from those of *BRCA1* HBC (Table 2): there is lesser aneuploidy and a lower mean aneuploid S phase fraction, which is more in line with the characteristics of non-HBC (Table 2). Estrogen receptor, progesterone receptor, p53 and Her2/*neu* proteins also appear to be expressed at levels comparable to those in non-HBC (Table 1).^{20,22,28-31,47-49}

KEY RESEARCH ACCOMPLISHMENTS & REPORTABLE OUTCOMES

- 285 cases ascertained for analysis
- 152 risk factor questionnaires have been completed
- 187 tumors analyzed by Dr. Joseph Marcus and Dr. David Page
- 98 additional cases to be added to Drs. Marcus and Page's analysis
- 70 cases have completed ER, PR, c-erbB-2 analysis

CONCLUSION & DISCUSSION

Clinical Implications of *BRCA1* and *BRCA2* HBC Pathophenotypes

The decreased estrogen and progesterone receptor expression suggests that *BRCA1* breast cancer generally will not respond well to therapy with hormone receptor modulators such as tamoxifen. However, we have cautioned⁵⁰ that this supposition should not preclude consideration of such therapy in chemoprevention trials, for there is no evidence that the pre-transformed target intermediate cell lacks receptors. Early data in the National Surgical Adjuvant Breast and Bowel Project prevention trial (NSABP-P1) indicate that tamoxifen may not reduce breast cancer incidence among *BRCA1* mutation carriers, but may reduce the incidence among *BRCA2* mutation carriers, whose tumors are usually estrogen receptor-positive when they develop (Table 1).⁵¹ However, the numbers of positive events in the trial currently is quite small and the results do not reach statistical significance for either *BRCA1* or *BRCA2* carriers. Clearly this and other trials with larger numbers of *BRCA1* and *BRCA2* mutation carriers and more extended follow-up times are needed before this issue can be properly addressed.

The prognosis of *BRCA1* HBC has been a matter of ongoing debate. The issue is important because it weighs in the decisions on prophylactic therapies. Most studies find no significant differences in survival in comparison with non-HBC,^{15,49,50,52-54} but better⁵⁵ and worse^{56,57} outcomes have also been reported. Methodologic differences may account in part for the variability in results.⁵⁸ Why the prognosis of *BRCA1*-related HBC, with its adverse pathology markers, would be no worse than non-HBC is a conundrum that is deepened by the observation that in the Creighton families, *BRCA1*-related HBC cases fare better than non-*BRCA1*-related HBC cases, which have neutral pathology indicators.^{15,50} But there are clues that *BRCA1* HBC is not an ordinary high grade breast cancer. As we have seen, it does not highly express *c-erbB2*, a marker of poor prognosis,^{22,29} and a high proportion are medullary carcinomas,^{13,15,16,17,24,25} which in pure forms are prognostically favorable, despite their high mitotic and nuclear grades.⁵⁹ Might genetic instability in *BRCA1* HBC – manifest by the prevalent aneuploidy, low aneuploid DNA index, and increased p53 expression described above – indicate fragility and increased susceptibility to chemotherapy and radiation therapy? These observations and questions point to directions for future investigation.

Less is known about the prognosis of *BRCA2* HBC. The best available evidence from several studies is that survivals probably do not differ from non-HBC when adjusted for other variables such as stage.⁶⁰

The pathobiologic features of *BRCA1* and *BRCA2* HBC summarized in Tables 1 and 2 offer some clues as to whether a patient in a family untested for the genes may lie in one or the other syndrome. However, these should not be regarded as sufficiently sensitive and specific to serve as a substitute for syndrome identification by direct genetic testing for germline mutations. Recently, a small number of *BRCA1* HBC, *BRCA2* HBC, and non-HBC tumors were looked at

for expression of 5361 genes by microarray technology.⁶¹ The analysis disclosed 176 genes that were differentially expressed in tumors with *BRCA1* vs. *BRCA2* mutations, and that the expression profiles could accurately classify the tumor as having arisen from a germline mutation in *BRCA1* or *BRCA2*. If these results can be confirmed with larger numbers of cases, this technology could become a powerful tool in diagnosing *BRCA1* or *BRCA2* mutation carrier status from the breast tumors directly.

Please see Appendix A for updated analysis on ER/PR/ c-erB-2 expression in BRCA1/2 breast cancer tumors.

References

1. Marcus J, Watson P, Linder-Stephenson L, et al. The pathobiology of BRCA1-linked and -unlinked hereditary breast cancer (HBC). *Modern Pathol* 1994;7:18A (Abstract).
2. Claus EB, Risch N, Thompson WD, et al. Relationship between breast histopathology and family history of breast cancer. *Am J Epidemiol* 1990;131:961-72.
3. Marcus J, Page D, Watson P, et al. High mitotic grade in hereditary breast cancer. *Lab Invest* 1988;56:61A (Abstract).
4. Mulcahy GM, Platt R. Pathologic aspects of familial carcinoma of the breast. In: Lynch HT, editor. *Genetics and Breast Cancer*. New York: Van Nostrand Reinhold, 1981:65-97.
5. Rosen PP, Lesser ML, Senie MA, Kinne DW. Epidemiology of breast carcinoma III: Relationship of family history to tumor type. *Cancer* 1982;50:171-9.
6. Erdreich LS, Asal NR, Hoge AF. Morphologic types of breast cancer: age, bilaterality, and family history. *Southern Med J* 1980;73:28-32.
7. LiVolsi VA, Kelsey JL, Fischer DB, et al.. Effect of age at first childbirth on risk of developing specific histologic subtype of breast cancer. *Cancer* 1982;49:1937-40.
8. Stalsberg H, Thomas DB, Noonan EA. The WHO collaborative study of neoplasia and steroid contraceptives. Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. *Cancer* 1989;44:399-409.
9. Lagios MD, Rose MR, Margolin FR. Tubular carcinoma of the breast: association with multicentricity, bilaterality, and family history of mammary carcinoma. *Am J Clin Pathol* 1980;73:25-30.
10. Mosimann S, Torhorst JKH, Weber W, et al. Histopathological aspects of familial breast cancer. In: Weber W, Laffer UT, Durig M, editors. *Hereditary Cancer and Preventive Surgery*. Karger: Basel, 1990:1-7.
11. Claus EB, Risch N, Thompson WD, et al. Relationship between breast histopathology and family history of breast cancer. *Cancer* 1993;71:147-53.

12. Glebov OK, McKenzie KE, White CA, et al. Frequent *p53* gene mutations and novel alleles in familial breast cancer. *Cancer Res* 1994;54:3703-9.
13. Marcus JN, Page DL, Watson P, et al. BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. *Cancer* 1997;80(suppl):543-56.
14. Marcus JN, Watson P, Page DL, et al. The pathology and heredity of breast cancer in younger women. *J Natl Cancer Inst Monogr* 1994;16:23-34.
15. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. *Cancer* 1996;77:697-709.
16. Marcus JN, Watson P, Page DL, et al. BRCA2 hereditary breast cancer pathophenotype. *Breast Cancer Res Treat* 1997;44:275-7.
17. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of *BRCA1* or *BRCA2* mutations and sporadic cases. *Lancet* 1997;349:1505-10.
18. Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. *Cancer Res* 1996;56:471-4.
19. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. *J Natl Cancer Inst* 1998;90:1138-45.
20. Lynch BJ, Holden JA, Buys SS, et al. Pathobiologic characteristics of hereditary breast cancer. *Hum Pathol* 1998;29:1140-4.
21. Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets B, et al. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. *Cancer Res* 1996;56:3216-9.
22. Jóhannsson OT, Idvall I, Anderson C, et al. Tumour biological features of *BRCA1*-induced breast and ovarian cancer. *Eur J Cancer* 1997;33:362-71.
23. Rahman N, Stratton MR. The genetics of breast cancer susceptibility. *Annu Rev Genet* 1998;32:95-121.

24. Armes JE, Egan AJM, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. *Cancer* 1998;83:2335-45.
25. Eisinger F, Jacquemier J, Charpin C, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. *Cancer Res* 1998;58:1588-92.
26. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. *J Clin Oncol* 2002;20:1480-90.
27. Marcus J, Linder-Stephenson L, Conway T et al. High S phase fraction in hereditary breast carcinoma. *Cytometry* 1993;14(Suppl 6):34 (Abstract).
28. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study. *Cancer Res* 1999;59:2011-7.
29. Lakhani SR, van de Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in *BRCA1* and *BRCA2*. *J Clin Oncol* 2002;20:2310-8.
30. Noguchi S, Kasugai T, Miki Y, et al Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. *Cancer* 1999;85:2200-5.
31. Thor AD, Moore DH, II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. *J Natl Cancer Inst* 1992;84:845-55.
32. Meyer JS, He W. High proliferative rates demonstrated by bromodeoxyuridine labeling index in breast carcinomas with p53 overexpression. *J Surg Oncol* 1994;156:146-52.
33. Greenblatt M, Chappuis P, Bond J, et al. *TP53* Mutations in breast cancer associated with *BRCA1* and *BRCA2* germline mutations: Distinctive spectrum and structural distribution. *Cancer Research* 2001;61:4092-7.
34. Bewtra C, Watson P, Conway T, et al. Hereditary ovarian cancer: a clinicopathological study. *Int J Gynecol Pathol* 1992;11:180-7.

35. Hartwell LH, Kastan MB. Cell cycle control and cancer. *Science* 1994;266:1821-928.
36. Shackney SE, Smith CA, Miller BW, et al. Model for the genetic evolution of solid tumors. *Cancer Res* 1989;49:3344-54.
37. Cornelisse CJ, Kuipers-Dijkhoorn N, van Vliet M, et al. Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss. *Int J Cancer* 1992;50:544-8.
38. Dutrillaux B, Gerbault-Seureau M, Remvikos Y, et al. Breast cancer genetic evolution: I. Data from cytogenetics and DNA content. *Breast Cancer Res Treat* 1991;19:245-55.
39. Remvikos Y, Gerbault-Seureau M, Magdelénat H, et al. Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis. *Breast Cancer Res Treat* 1992;23:43-9.
40. Meyer JS. Cellular proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine: effects of menstrual phase, age, and oral contraceptive hormones. *Human Pathol* 1977;8:67-81.
41. Russo J, Calaf G, Roi L, et al. Influence of age and gland topography on cell kinetics of normal human breast tissue. *J Natl Cancer Inst* 1987;78:413-8.
42. Olsson H, Ranstam J, Baldetorp B, et al. Proliferation and DNA ploidy in malignant breast tumors in relation to early oral contraceptive use and early abortions. *Cancer* 1991;67:1285-90.
43. Holt JT, Thompson ME, Szabo CI, et al. Growth retardation and tumour inhibition by BRCA1. *Nat Genet* 1996;12:298-302.
44. Jarvis EM, Kirk JA, Clarke CL. Loss of nuclear *BRCA1* expression in breast cancers is associated with a highly proliferative tumor phenotype. *Cancer Genet Cytogenet* 1998;101:109-15.
45. Thompson ME, Jensen RA, Obermiller PS, et al. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. *Nat Genet* 1995;9:444-50.

46. Agnarsson BA, Jonasson JG, Björnsdóttir IB, et al. Inherited BRCA2 mutation associated with high grade breast cancer. *Breast Cancer Res Treat* 1998;47:121-7.
47. Karp SE, Tonin PN, Begin LR, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. *Cancer* 1997;80:435-41.
48. Loman N, Johannsson O, Bendahl P-O, et al. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. *Cancer* 1998;83:310-9.
49. Verhoog LC, Brekelmans CTM, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of *BRCA1*. *Lancet* 1998;351:316-21.
50. Watson P, Marcus JN, Lynch HT. Prognosis of *BRCA1* hereditary breast cancer. *Lancet* 1998;351:304-5.
51. King M-C, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in *BRCA1* and *BRCA2*: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. *JAMA* 2001;286:2251-6.
52. Gaffney DK, Brohet RM, Holden JA, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. *Radiotherapy Oncol* 1998;47:129-36.
53. Hamann U, Sinn H-P. Survival and tumor characteristics of German hereditary breast cancer patients. *Breast Cancer Res Treat* 2000;59:185-92.
54. Jóhannsson OT, Ranstam J, Borg Å, et al. Survival of *BRCA1* breast and ovarian cancer patients: a population-based study from southern Sweden. *J Clin Oncol* 1998;16:397-404.
55. Porter DE, Cohen BB, Wallace MR, et al. Breast cancer incidence, penetrance and survival in probable carriers of *BRCA1* gene mutation in families linked to *BRCA1* on chromosome 17q12-21. *Br J Surg* 1994;81:1512-5.
56. Foulkes WD, Wong N, Brunet J-S, et al. Germ-line *BRCA1* mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. *Clin Cancer Res* 1997;3:2465-9.

57. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al. Familial invasive breast cancers: worse outcome related to *BRCA1* mutations. *J Clin Oncol* 2000;18:4053-9.
58. Phillips K-A, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in *BRCA1* or *BRCA2*: Are they prognostically different? *J Clin Oncol* 1999;17:3653-63.
59. Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. *Cancer* 1977;40:1365-85.
60. Verhoog LC, Berns EMJJ, Brekelmans CTM, et al. Prognostic significance of germline *BRCA2* mutations in hereditary breast cancer patients. *J Clin Oncol* 2000;18:119s-24s.
61. Hedenfalk I, Duggan D, Chen Y, et al. Gene expression profiles in hereditary breast cancer. *N Engl J Med* 2001;344:539-48.

Table 1: Pathobiologic Characteristics of BRCA1 and BRCA2 Compared With Non-Hereditary Breast Cancers: Literature Summary			
Characteristic	BRCA1	BRCA2	References
Histologic type			
Medullary and atypical medullary	↑	↔?	Marcus et al (1996, 1997a, 1997b); Breast Cancer Linkage Consortium (1997); Armes et al (1998); Eisinger et al (1998)
Lobular and variants	↓	↑?	BRCA1: Marcus (1997a); BRCA2: Armes et al (1998a)
Tubular-lobular group	↓	↑?	Marcus et al (1996, 1997a)
Any DCIS	↓	↔	Marcus et al (1996); Breast Cancer Linkage Consortium (1997)
Any LCIS	↓	↔?	Marcus et al (1996); Breast Cancer Linkage Consortium (1997)
Histologic grade			
Total	↑	↔?	Marcus et al (1996, 1997a,b); Eisinger et al 1996; Breast Cancer Linkage Consortium (1997); Johannsson et al (1997); Armes et al (1998a); Lynch et al (1998); Noguchi et al (1999)
Tubular	↑	↑	BRCA1: Marcus et al (1996, 1997a); Eisinger et al (1996); BRCA1 and BRCA2: Breast Cancer Linkage Consortium (1997); Lakhani et al (1998)
Nuclear	↑	↔?	BRCA1: Eisinger et al (1996); BRCA1 and BRCA2: Breast Cancer Linkage Consortium (1997)
Mitotic	↑	↔?	Marcus et al (1996, 1997a, 1997b); Eisinger et al (1996); Breast Cancer Linkage Consortium (1997); Lynch et al (1998); Lakhani et al (1998)
DNA cytometry			
Diploidy	↓	↔	Marcus et al (1996, 1997a, 1997b); Johannsson et al (1997)
Non-diploid S-phase fraction	↑	↔	Marcus et al (1996, 1997a, 1997b); Johannsson et al (1997)
Protein markers			
Estrogen receptor	↓	↔	Johannsson et al (1997); Karp et al (1997); Verhoog et al (1998); Lynch et al (1998); Loman et al (1998); Noguchi et al (1999); Stoppa-Lyonnet et al (2000); Lakhani et al (2002)
Progesterone receptor	↓	↔	Johannsson et al (1997); Verhoog et al (1998); Lynch et al (1998); Loman et al (1998); Stoppa-Lyonnet et al (2000); Lakhani et al (2002)
p53	↑	↔	Thor et al (1992); Armes et al (1998b); Lynch et al (1998); Noguchi et al (1999); Lakhani et al (2002)
<i>c-erbB2</i> (Her2/neu)	↓	↔	Johannsson et al (1997); Noguchi et al (1999); Lakhani et al (2002)

Symbols in columns 2 and 3 indicate increased (↑), decreased (↓), or similar (↔) incidence of a characteristic as compared with non-hereditary breast cancer. “?” in column 3 indicates non-unanimity in the literature and evidence for possible heterogeneity in *BRCA2* HBC

Table 2: BRCA1 vs. BRCA2 Hereditary Breast Cancer: The Creighton University Series¹			
	BRCA1	BRCA2	p ²
<i>Number of families with pathology assessment</i>	29	10	
<i>Number of invasive carcinomas in females</i>	108 ³	37 ³	
Clinical Features			
<i>Age of onset (mean ± SD) (yr)</i>	42.9 ± 12.6	49.1 ± 12.3	0.011
<i>Bilateral cases</i>	34 (31.5%)	8 (21.6%)	0.30
<i>Male cases (excluded)</i>	2	2	
<i>Tumor size (mean ± SD) (cm)</i>	2.1 ± 1.3	1.8 ± 1.2	0.25
<i>Lymph node-positive cases</i>	30 (31.9%)	12 (50.0%)	0.15
Pathologic Types and Features			
Medullary group (medullary, atypical medullary, ductal with medullary features)	43 (40.6%)	4 (12.5%)	0.003
Tubular-lobular group (lobular, tubulolobular, tubular, cribriform special types and variants)	14 (13.2%)	15 (46.9%)	0.0001
Any ductal carcinoma in situ (DCIS)	31 (28.7%)	20 (54.0%)	0.009
Any lobular carcinoma in situ (LCIS)	2 (1.9%)	5 (13.5%)	0.012
Any lobular neoplasia (LCIS + atypical lobular hyperplasia)	3 (2.5%)	11 (29.7%)	<0.0001
Mononuclear cell infiltration absent	3 (9.4%)	9 (27.5%)	0.019
Pathologic Grades			
Mitotic grade 3	43 (53.1%)	6 (25.0%)	0.020
Nuclear grade 3	45 (55.1%)	2 (8.3%)	<0.0005
Tubular grade 3	72 (88.9%)	19 (79.2%)	0.30
Final grade 3	39 (56.5%)	4 (21.1%)	0.009
DNA Cytometry			
Diploid	10 (14.9%)	10 (50.0%)	0.002
Non-diploid	57 (85.1%)	10 (50.0%)	
S-phase fraction, diploids (mean ± SD, %)	2.78 ± 1.73 n = 10	3.53 ± 1.73 n = 10	0.48
S-phase fraction, non-diploids (mean ± SD, %)	15.77 ± 6.82 n = 56	7.36 ± 4.87 n = 10	<0.0005

- 1) Fisher's exact test for 2 × 2 tables or 2-tailed Student t-test for means and standard deviations.
- 2) The numbers of cases simultaneously reviewed by the project pathologists (J. N. Marcus and D. L. Page). The denominators implicit from the percent figures that follow are sometimes less than these totals if not every tumor was available for assessment of a given feature.

Appendix A

Pathobiology of BRCA1 and BRCA2 Hereditary Breast Cancers: Update of c-erbB2 Expression, Steroid Hormone Receptor Expression, and DNA Ploidy and S-phase Analysis Studies.

Introduction

Most cases of breast cancer are sporadic. Hereditary breast cancer (HBC) accounts for about 5 to 10% of all breast cancers. Of these, loss of function mutations of the BRCA1 and BRCA2 tumor-suppressor genes are found in the majority of HBC cases. Decreased BRCA1 expression may also occur in some sporadic tumors (Wilson et al., 1999). Study of HBC has led to valuable insight into the pathobiology of breast cancer associated with loss of function of these genes. Both BRCA1 and BRCA2 HBC present at an earlier mean age than non-hereditary breast cancer (nHBC) and BRCA1 and BRCA2 associated HBC exhibit distinct pathobiological features in comparison with nHBC (Marcus et al., 1996 & 1997; Johannsson et al., 1997).

Herein we compare c-erbB2, estrogen receptor (ER) and progesterone receptor (PR) expression in invasive breast carcinomas from HBC patients with known BRCA1 and BRCA2 mutations. We also report the DNA ploidy and S-phase fractions for these neoplasms as determined by flow cytometry. Our findings confirm our previous observations of the pathophenotype of BRCA1 hereditary breast cancers and provide evidence for a distinct, more aggressive pathobiological BRCA2 phenotype compared to previous results.

Methods

Patients. Forty-four patients from BRCA1 HBC families and 26 patients from BRCA2 HBC families meeting study criteria were identified from a larger cohort of HBC patients followed by the hereditary cancer surveillance program headed by Dr. Henry Lynch at the Creighton University School of Medicine. Patients included in the study had a tissue diagnosis of invasive breast carcinoma, known BRCA1 or BRCA2 mutations, and available pathology specimens representative of their primary neoplasm. Informed consent from patients or their survivors and institutional research board approval were obtained prior to the study.

Mutation Analysis. Mutation analysis for BRCA1 and BRCA2 point mutations, insertions and deletions was performed using peripheral lymphocytes as previously described (Puget et al., 1999). Germline BRCA mutation was verified directly in each patient; except for two patients (one BRCA1 and one BRCA2) confirmed to be obligate mutation carriers by demonstration of their respective familial mutations in their offspring.

Immunohistochemistry. Immunostaining was performed on 4.0 micron-thick paraffin-embedded sections heat-fixed on poly-l-lysine-coated glass slides using a Ventana ES automated immunostainer (Ventana Medical Systems, Tucson, AZ). Anti-c-erbB2, a mouse monoclonal antibody (clone CB11) raised against a synthetic peptide corresponding to an internal domain of c-erbB2, was obtained from Ventana. ER- and PR-specific antibodies (clones 6F11& 1A6) were also obtained from Ventana. Only the invasive component of neoplasms were scored for immunoreactivity, *i.e.*, carcinoma *in situ* (CIS) was ignored. C-erbB2 immunostained tumor tissue sections displaying moderate to strong circumferential membrane immunoreactivity were scored as positive. Positive ER and PR immunoreactivity of at least approximately 5% of the neoplastic cell nuclei in the section was scored as positive expression.

Flow Cytometry. For each tumor sample with adequate available tissue two 50 micron-thick sections from formalin-fixed, paraffin-embedded blocks were de-waxed, pepsinized, and stained with propidium iodide using a modified Hedley method (Crissman, et al., 1988). The resultant DNA-stained suspension of extracted nuclei was processed on an EPICS XL-MCL flow cytometer (Coulter Electronics, Hialeah FL), and the accumulated histogram analyzed with MULTICYCLE for WINDOWS (Phoenix Flow Systems, San Diego, CA. 1998). DNA histograms were classified and scored with regard to DNA ploidy and percent S-phase fraction, as previously described (Marcus et al., 1996).

Results

c-erbB2 and Steroid Hormone Expression. Paraffin-embedded samples of 44 invasive carcinomas from individuals with BRCA1 mutations and 25 from individuals with BRCA2 mutations were available for

immunostaining. Tumor specimens from 5 out of 44 BRCA1 HBC patients, or 11.4% displayed immunoreactivity indicative of c-erb2b overexpression (Tables 1 & 3). Twelve out of 25, or 48.0% of specimens from BRCA2 patients showed c-erb2b overexpression (Tables 2 & 3). Tumor cell expression of ER, PR or both was detected in 29.5% (13/44) of BRCA1 patients and 68.0% (17/25) of BRCA2 patients (Tables 1 & 2). Four of 44 (9.1%) of BRCA1 samples and 4 of 25 (16.0%) of BRCA2 samples were ER+ and PR-. No patient samples were PR+ and ER- in either group.

DNA Analysis. Tumor DNA ploidy and percent S-phase fraction analysis also differed between the two groups (Tables 1, 2 & 4). Twenty-five percent of BRCA1 tumors evaluated by flow cytometry (9/36) were diploid and 75.0% (27/36) were aneuploid. The DNA indices of the aneuploid BRCA1 tumors ranged from 1.12 to 2.44 with a mean of 1.64. Six near-tetraploid neoplasms (DNA indices 1.80 to 2.10) were identified. The S-phase fraction ranged from 0.9 % to 5.5 % in diploid BRCA1 tumors and 1.2% to 35.7% in aneuploid BRCA1 tumors. The average S-phase fractions were 2.5% and 13.0% for diploid and aneuploid tumors, respectively.

Among BRCA2 mutation-positive tumors 34.8% (8/23) were diploid and 65.2% (15/23) aneuploid. The DNA index of the aneuploid tumors ranged from 1.07 to 1.94 with a mean of 1.50. Two tumors were near-tetraploid (DNA indices 1.84 to 1.94). The S-phase fractions ranged from 0.4 % to 5.7% for the diploid BRCA2 tumors and 1.8% to 26.0% for the aneuploid BRCA2 breast cancers. The average S-phase fractions were 2.0% for diploid tumors and 7.8% for aneuploid tumors. The average Chi square value for all specimens was 6.1 (range 1.4 to 20.4).

Discussion

The BRCA1 protein is involved in a response to DNA damage and appears to regulate effectors controlling the G2/M cell cycle checkpoint (Yarden et al., 2002) and it is thus not surprising that BRCA1 mutant tumors display a high proliferative index. The function of BRCA2 appears to be to facilitate repair of DNA double stranded breaks and its loss is thought to lead to dependence on less reliable repair mechanisms and chromosome instability (Larminat et al., 2002).

Tumor aneuploidy is generally associated with aggressive neoplasms. The significance of DNA index as a prognosticator of the biological behavior of breast cancer is debatable; however, hypodiploidy and near-tetraploidy appear to be associated with more aggressive breast neoplasms (Hedley et al., 1993). No definitive examples of hypodiploidy could be demonstrated in this series. More of the BRCA1 aneuploid tumors were near-tetraploid (6/27 or 22.2%) than the BRCA2 aneuploid tumors (2/15 or 13.3%). The fact that a high degree of aneuploidy in general is observed in BRCA1 tumors may not contribute to more aggressive biological behavior compared to nHBC, but may simply be a consequence of genomic instability created by loss of G2/M checkpoint control with DNA damage. Consistent with this is the fact that the aneuploid BRCA1 tumors showed high S-phase fractions. High S-phase fraction and negative steroid hormone receptor expression correlate more strongly with aggressive clinical behavior of breast cancer than does DNA ploidy (Hedley et al., 1993; Wegner et al., 1998). These characteristics do suggest that BRCA1 HBC should behave in a more malignant manner than BRCA2 HBC and nHBC. The oncoprotein c-erbB2 is a member of the epidermal growth factor receptor family. Overexpression of c-erbB2 in breast cancers is associated with shortened survival time (Hanna et al., 1994). The relatively low c-erbB2 overexpression rate observed in this series of BRCA1 HBC (11.4 % of cases vs. 16 – 20% of cases in sporadic cancers (Hanna et al., 1994; Hartmann et al., 2001)), however, may partially explain why despite its other aggressive features, BRCA1 is associated with similar survival rates as nHBC (Watson et al., 1998).

Overexpression of c-erbB2 appears to be an independent of estrogen receptor expression as a prognosticator of response to endocrine therapy. Houston et al. (1999) found that c-erbB+ patients had shorter times to progression while on Tamoxifen therapy compared to control patients. The data presented here suggests that a significant percentage of BRCA2 HBC patients may fit in this situation. Adjuvant chemotherapy or immunotherapy with Herceptin[™], however, may increase the survival of c-erbB2-overexpression positive patients to that comparable to c-erbB2 negative patients. Given the high degree of c-erbB2 expression observed in BRCA2 tumors (Table 3) and otherwise potentially aggressive phenotype of BRCA1 tumors, early establishment of the c-erbB2 status in HBC patients may be even more clinically important than in nHBC in general.

Conclusions

This study confirms previous data showing that BRCA1 HBC displays an aggressive biological phenotype characterized by high S-phase fraction and low estrogen and progesterone receptor expression. C-erbB2 oncoprotein expression was low, however, which may partially explain why BRCA1 HBC tends to have a prognosis no worse than nHBC. BRCA2 cancers showed a slightly lower average S-phase fraction and higher degree of steroid hormone receptor expression than BRCA1 cancers, but also showed a level of c-erbB2 expression about 2.5 times higher than seen in sporadic breast cancers (48% of cases vs. 16 – 20% of cases). This suggests a somewhat more aggressive BRCA2 phenotype than previously thought, as suggested by Agnarsson et al. (1998), and underscores the importance of c-erbB2 testing in HBC as well as nHBC.

References

- Agnarsson BA, Jonasson JG, Bjornsdottir IB, Barkardottir RB, Egilsson V, Sigurdsson H. Inherited BRCA2 mutation associated with high grade breast cancer. *Breast Cancer Res Treat* 47:121-7 (1998).
- Crissman JD, Zarbo RJ, Niebylski CD, Corbett T, Weaver D. Flow cytometric DNA analysis of colon adenocarcinomas: a comparative study of preparatory techniques. *Mod Pathol* 1:198-204 (1988).
- Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. *Mod Pathol* 14:677-85 (2001).
- Hartmann LC, Ingle JN, Wold LE, Farr GH Jr, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. *Cancer* 74:2956-63 (1994).
- Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus Review of the clinical utility of DNA cytometry in carcinoma of the breast. *Cytometry* 14:482-485 (1993).
- Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. *Br J Cancer* 79:1220-6 (1999).
- Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, Olsson H. Tumour biological features of BRCA1-induced breast and ovarian cancer. *Eur J Cancer* 33:362-71 (1997).
- Larminat F, Germanier M, Papouli E, Defais M. Deficiency in BRCA2 leads to increase in non-conservative homologous recombination. *Oncogene* 21:5188-92 (2002).
- Marcus J, Page D, Watson P, Conway T, Lynch H. High mitotic grade in hereditary breast cancer. *Lab Invest* 58:60A (1988).
- Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. *Cancer* 77:697-709 (1996).
- Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT. BRCA2 hereditary breast cancer pathophenotype. *Breast Cancer Res Treat.* 44:275-7 (1997).
- non-inherited breast carcinomas. *Nat Genet* 21:236-40 (1999).
- Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, Mazoyer S. Screening for germline rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. *Cancer Res* 59:455-61 (1999).
- Watson P, Marcus JN, Lynch HT. Prognosis of *BRCA1* hereditary breast cancer. *Lancet*;351:304-5 (1998).
- Wenger CR, Clark GM. S-phase fraction and breast cancer--a decade of experience. *Breast Cancer Res Treat* 51:255-265 (1998).

Wilson, CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. Localization of human BRCA1 and its loss in high-grade,

Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30:285-9 (2002).

Table 1: DNA Analysis , Steroid Hormone Receptor and c-erbB2 Expression in BRCA1 Mutation Breast Carcinomas. For hormone receptor and c-erbB2 expression 1 indicates positive and 0 negative immunoreactivity. M denotes male patients and NA indicates data not available.

<u>Patient</u>	<u>DNA Index</u>	<u>%S-Phase</u>	<u>%Total</u>	<u>X2</u>	<u>ER</u>	<u>PR</u>	<u>c-erbB2</u>	<u>BRCA</u>
1	1.599	35.7	5.2	4.8	0	0	0	1
2	1.552	20.2	25.5	3.9	0	0	0	1
3	1.605	6.5	19.7	8.8	0	0	0	1
4	1	5.5	100	1.9	0	0	0	1
5	1.432	14.5	70.5	7	0	0	0	1
6	1.493	20.3	62.8	1.4	1	0	0	1
7	1.117	18.6	4.4	1.6	0	0	0	1
8	1.638	5.8	77.9	2.2	1	1	0	1
9	1.802	4.3	48.4	3.5	0	0	0	1
10	1	1.5	100	1.6	0	0	0	1
11	1.83	18.9	21.1	3.5	0	0	0	1
12	1.186	4.1	11.8	5.4	1	1	0	1
13	1	1.3	100	13.4	0	0	1	1
14	1	3.4	100	1.7	0	0	0	1
15	2.021	9.6	13.8	11.5	1	1	0	1
16	1.402	7.9	26.4	2.7	0	0	0	1
17	1.68	19.9	13	20.4	0	0	0	1
18	1	1	100	7.6	0	0	0	1
19	NA	NA	NA	NA	1	1	0	1
20	1.672	13.7	10.4	5.5	1	0	0	1
21	1.897	1.2	33.7	14.1	1	1	1	1
22	1.326	27.9	9	7.2	0	0	0	1
23	1.651	24.5	8.4	13.4	0	0	0	1
24	1.897	12.7	49	1.9	0	0	1	1
25	2.097	15.7	10.5	12.3	0	0	0	1
26	1	2.1	100	1.7	0	0	0	1
27	1.135	2	56.4	2	1	1	1	1
28	1.732	10.3	20.4	4.7	0	0	0	1
29	NA	NA	NA	NA	0	0	1	1
30	1.411	9.3	4.9	9.1	0	0	0	1
31	1.586	5.5	28.8	2.1	1	1	0	1
32	2.436	13.3	20.2	2.4	0	0	0	1
33	1.722	14	36	6.5	0	0	0	1
34	1.881	5.8	23.7	2	1	1	0	1
35	1	1	100	11.5	0	0	0	1
36	1	0.9	100	5.7	1	1	0	1
37	1.554	8	32.9	7.4	0	0	0	1
38	NA	NA	NA	NA	1	0	0	1
39	1	5.4	100	3.2	0	0	0	1
40	NA	NA	NA	NA	0	0	0	1
41	NA	NA	NA	NA	0	0	0	1
42	NA	NA	NA	NA	0	0	0	1
43	NA	NA	NA	NA	0	0	0	1
44	NA	NA	NA	NA	1	0	0	1

Table 2: DNA Analysis , Steroid Hormone Receptor and c-erbB2 Expression in BRCA2 Mutation Breast Carcinomas. For hormone receptor and c-erbB2 expression 1 indicates positive and 0 negative immunoreactivity. M denotes male patients and NA indicates data not available.

<u>Patient</u>	<u>DNA Index</u>	<u>%S Phase</u>	<u>%Total</u>	<u>X2</u>	<u>ER</u>	<u>PR</u>	<u>c-erbB2</u>	<u>BRCA</u>
1	1.477	6.6	18.6	5.5	0	0	0	2
2	1	3	100	12	NA	NA	NA	2
3	1	0.4	100	1.9	1	1	1	2
4	1.355	26	6.7	4.1	1	0	0	2
5	1	1.3	100	6.4	1	1	0	2
6	1.943	2.2	27	4.7	0	0	0	2
7	1	1.5	100	8.8	1	1	1	2
8	1	5.7	100	3.4	1	0	1	2
9	1.471	9.8	34.6	3.3	0	0	0	2
10	1.698	8.6	40	13.4	1	1	1	2
11	1.116	2.7	19.6	6.1	0	0	1	2
12	1.377	14.9	33.1	19.9	0	0	1	2
13	1.143	1.9	50.6	1.4	1	1	0	2
14	1.841	6.6	63.8	2.7	1	1	0	2
15	1.79	4.3	37.4	3.6	1	1	1	2
16	1	0.7	100	2.3	1	1	1	2
17	1.244	1.8	88.5	3.4	0	0	1	2
18	1.651	4.4	8.6	13.3	1	1	0	2
19	1.599	5.7	23.5	7.8	0	0	1	2
20	1.658	18	3.5	6.4	1	0	1	2
21	1	1.2	100	2.2	1	1	0	2
22	1	2.2	100	3	1	1	1	2
23	1.07	3.5	77.3	6.3	1	1	0	2
24	NA	NA	NA	NA	0	0	0	2
25	NA	NA	NA	NA	1	0	0	2
26	NA	NA	NA	NA	1	1	0	2

Table 3: c-erbB2 and Steroid Hormone Receptor Expression in HBC.

	BRCA1	BRCA2
c-erbB2	5/44 (11.4%)	12/25 (48.0%)
Estrogen Receptor	13/44 (29.5%)	17/25 (68.0%)
Progesterone Receptor	9/44	13/25

Table 4: DNA Ploidy and Percent S-phase Fraction in HBC.

	BRCA1	BRCA2
Diploid	9/36 (25.0%)	8/23 (34.8%)
Diploid %S-phase (mean)	0.9 – 5.5 (2.5)	0.4 – 5.7 (2.0)
Aneuploid	27/36 (75.0%)	15/23 (65.2%)
Aneuploid %S-phase (mean)	1.2 – 35.7 (13.0)	1.8 – 26 .0 (7.8)
DNA Index (mean)	1.12 – 2.44 (1.64)	1.07 – 1.94 (1.50)